Pfizer’s Rita Balice-Gordon has joined Sanofi as the French company’s new head of neurobiology research. At Pfizer Rita served as head of circuits, neurotransmitters and signalling in its neuroscience and pain research unit. Prior to that, she was professor of neuroscience and chair of the neuroscience graduate group in the Perelman School of Medicine at the University of Pennsylvania.
Faron Pharmaceuticals has appointed Matti Karvonen as its new Medical Director. Matti will be responsible for overseeing Faron's drug development strategy and will play a central role in expanding the clinical programmes of Traumakine and Clevegen. Matti has a background in clinical neurology with a deep medical experience in many international pharmaceutical organisations, including Roche, Biogen Idec and Novartis, and has participated in many clinical programmes, most recently in the pan-European launch of a new neurological drug. In the early part of his career he held several research positions and he has also co-founded several commercial medical organisations.
Laboratoris Sanifit, a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, has appointmented Keith Leonard to the board of directors. Keith was co-founder, president and CEO of Kythera Biopharmaceuticals from 2005 until its acquisition by Allergan in October 2015 for $2.1 billion. Prior to that he held various positions at Amgen, including the creation of Amgen's Rheumatology Business Unit, and as senior vice president and general manager of Amgen Europe, responsible for commercial operations in 28 European countries.
Antia Buhigas has joined Red Door Unlimited to help deliver a new consumer health proposition, whilst advising on social strategy across the ethical PR portfolio. She'll be making use of her integrated experience to bring together the best minds inside and outside the Creston Unlimited group to collaborate in programmes that excite and educate in equal measure – and drive behaviour change. Antia has led engagement strategy on behalf of complex organisations for over 15 years, including Pegasus, with its mixed client base, PhotoBox, Merlin Entertainments Group and Jack Morton to name a few.
90TEN has appointed Willoughby Badger as an account director, Deepa Patel as an account manager and Anna Reidinger as an assistant account executive to the agency's PR division. Willoughby joins from inVentiv Health agency Biosector 2, where he held responsibility for global advocacy programmes. Prior to Biosector 2, he began his career on the Chandler Chicco Companies graduate scheme and was a finalist for the 2013 Communiqué Young Communicator of the Year Award. Deepa moves to 90TEN following three years at Tonic Life Communications, where she worked on international accounts spanning oncology, neurology and medical devices. Prior to this, she served as a clinical trials data manager for Coventry and Warwickshire NHS Trust. Anna has recently graduated with a first class honours degree in biomedical science and previously conducted research into HIV at the prestigious Chelsea and Westminster Hospital in London.
DiCE Molecules, a privately held company developing a next generation approach to small molecule drug discovery, has appointed Richard Scheller, chief scientific officer and head of therapeutics at 23andMe, to its board of directors. Richard brings to DiCE nearly 20 years of leadership in drug discovery research and development. Prior to 23andMe, he spent 14 years at Genentech, where he served in various research and development roles until his retirement. Most recently, he was executive vice president of research and early development, focusing on the company's research strategy, drug discovery, business development and early drug development activities.
Lucid Group has welcomed three new employees to its team. Laura Cunliffe joins as a senior account manager at Leading Edge. She is an experienced account handler with over six years' experience working in healthcare communications. Cynthia Chen joins Lucid Partners as a senior medical writer. Cynthia is an accomplished medical writer and academic who holds a PhD and two MSc degrees in multiple biomedical and bioethics disciplines. Cynthia brings a wealth of medical writing capabilities and insights into numerous therapeutic areas. Lucid Group have also expanded its team of Futures Executives with the hire of Chloe Powell. Chloe was working as a post-doctoral researcher at the University of Oxford after completing her DPhil in Pharmacology. Lucid has been running the Futures Programme for 4 years with the aim of nurturing the top talent emerging from universities.
Publicis Life Brands Resolute (PLBR) has further bolstered its senior team with the appointment of two new hires. Glen Halliwell joins the business as associate director, in charge of all medical education accounts, and Susan Rome joins as director of scientific strategy. With more than a decade of healthcare communications experience behind him, Glen specialises in designing, planning and running medical education programmes. As a previous Resolute employee, his appointment marks a return to the company after seven years away. As director of scientific strategy, Susan will blend scientific, strategic and creative expertise to develop insightful brand strategy and support the team to communicate complex information in a simple, impactful way. Susan brings with her over 15 years of experience developing educational and promotional communications with global and regional reach, and spanning diverse therapy areas.
Lansons has recruited Kate Aldous as associate director to join the healthcare team. Kate has 11 years’ health communications experience and has led ethical and consumer healthcare campaigns for leading pharmaceutical companies at a UK and global level. She joins Lansons from Red Door Unlimited where she provided senior level consultancy to clients including Sanofi, Astellas, Pfizer, Novartis, MSD, Lilly and AstraZeneca.
Jeremy Haigh will be joining the board of Proteome Sciences as CEO in June. He is a strong advocate of precision medicine and will bring numerous industry contacts and considerable commercial experience to the role. Jeremy is an established leader in the biopharmaceutical sector with 30 years in clinical and operational research and development, principally at Merck and Amgen where most recently he was European chief operating officer, R&D.